EFTA00847263

From: Richard Kahn To: Jeffrey Epstein leevacation@gmail.com> Subject: Mrk Date: Wed, 02 Sep 2015 10:52:53 +0000 PivIRK Chart MRK data by YCharts 4. Merck & Co. (MRK) Credit Suisse Rating, Target Price: Neutral, S61 Potential Stock Upside: 11% Upcoming Catalyst: MRK's Januvia franchise will likely feel pressure from the positive EMPA-REG OUTCOME data but we expect MRK to get a boost from FDA approval of Keytruda in 2nd line NSCLC soon (FDA action date Oct 2) and its HCV doublet grazoprevir/elbasvir by early next year (FDA action date Jan 28). TheStreet Rating: Buy, B+ TheStreet Said: TheStreet Ratings team rates MERCK & CO as a Buy with a ratings score of B+. TheStreet Ratings Team has this to say about their recommendation: "We rate MERCK & CO (MRK) a BUY. This is driven by several positive factors, which we believe should have a greater impact than any weaknesses, and should give investors a better performance opportunity than most stocks we cover. The company's strengths can be seen in multiple areas, such as its largely solid financial position with reasonable debt levels by most measures, notable return on equity, reasonable valuation levels, good cash flow from operations and expanding profit margins. We feel its strengths outweigh the fact that the company has had sub par growth in net income." Highlights from the analysis by TheStreet Ratings Team goes as follows: The current debt-to-equity ratio, 0.57, is low and is below the industry average, implying that there has been successful management of debt levels. Along with the favorable debt-to-equity ratio, the company maintains an adequate quick ratio of 1.02, which illustrates the ability to avoid short-term cash problems. Current return on equity exceeded its ROE from the same quarter one year prior. This is a clear sign of strength within the company. Compared to other companies in the Pharmaceuticals industry and the overall market, MERCK & CO's return on equity exceeds that of both the industry average and the S&P 500. EFTA00847263 Net operating cash flow has increased to $2,585.00 million or 11.66% when compared to the same quarter last year. The firm also exceeded the industry average cash flow growth rate of -10.37%. The gross profit margin for MERCK & CO is currently very high, coming in at 79.15%. It has increased from the same quarter the previous year. Regardless of the strong results of the gross profit margin, the net profit margin of 7.01% trails the industry average. You can view the full analysis from the report here: MRK Ratings Report Sent from my iPhone EFTA00847264